Show simple item record

dc.contributor.authorGarne, Esteren_US
dc.contributor.authorHansen, Anne Vinkelen_US
dc.contributor.authorMorris, Joanen_US
dc.contributor.authorKlungsøyr, Karien_US
dc.PublishedJournal of Allergy and Clinical Immunology 2015, 136(6):1496-1502eng
dc.description.abstractBackground. Pregnant women with asthma need to take medication during pregnancy. Objective. We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy. Methods. We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 registrations of congenital anomalies from 13 EUROmediCAT registries. Results. Cleft palate (OR, 1.63; 95% CI, 1.05-2.52) and gastroschisis (OR, 1.89; 95% CI, 1.12-3.20) had significantly increased odds of exposure to first-trimester use of inhaled β2-agonists compared with nonchromosomal control registrations. Odds of exposure to salbutamol were similar. Nonsignificant ORs of exposure to inhaled β2-agonists were found for spina bifida, cleft lip, anal atresia, severe congenital heart defects in general, or tetralogy of Fallot. None of the 4 literature signals of exposure to inhaled steroids were confirmed (cleft palate, cleft lip, anal atresia, and hypospadias). Exploratory analyses found an association between renal dysplasia and exposure to the combination of long-acting β2-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85). Conclusions. The study confirmed increased odds of first-trimester exposure to inhaled β2-agonists for cleft palate and gastroschisis and found a potential new signal for renal dysplasia associated with combined long-acting β2-agonists and inhaled corticosteroids. Use of inhaled corticosteroids during the first trimester of pregnancy seems to be safe in relation to the risk for a range of specific major congenital anomalies.en_US
dc.rightsAttribution CC BY-NC-ND 4.0eng
dc.subjectAsthma medicationeng
dc.subjectcongenital anomalieseng
dc.subjectfirst trimester exposureeng
dc.subjectinhaled β2-agonistseng
dc.subjectinhaled β2-agonistseng
dc.titleUse of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control studyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2015 The Authors
dc.subject.nsiVDP::Medisinske Fag: 700en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY-NC-ND 4.0
Except where otherwise noted, this item's license is described as Attribution CC BY-NC-ND 4.0